• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童急性髓系白血病首次异基因造血干细胞移植后复发的结局:333 例回顾性 I-BFM 分析。

Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.

机构信息

Division of Pediatric Hematology and Oncology, Department of Pediatrics, Universities of Medical University Hannover, Hannover, Germany.

IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.

出版信息

Br J Haematol. 2020 May;189(4):745-750. doi: 10.1111/bjh.16441. Epub 2020 Feb 3.

DOI:10.1111/bjh.16441
PMID:32012224
Abstract

Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.

摘要

分析了 333 例首次异基因造血干细胞移植后复发的急性髓系白血病儿童的结果。总生存 4 年的概率(4y-pOS)为 14%。接受第二次造血干细胞移植的 122 名儿童的 4y-pOS 为 31%,未接受第二次移植的为 3%(P<0.0001)。获得后续缓解对生存有影响(P<0.0001)。对于接受第二次移植的患者,无论是否获得后续缓解,其生存情况相似。移植来源(骨髓与外周血干细胞,P=0.046)和供者选择(匹配的亲缘供者与匹配的无关供者,P=0.029)对复发后的生存有积极影响。复发后 4 年疾病复发和非复发死亡率达到 45%和 22%。

相似文献

1
Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.儿童急性髓系白血病首次异基因造血干细胞移植后复发的结局:333 例回顾性 I-BFM 分析。
Br J Haematol. 2020 May;189(4):745-750. doi: 10.1111/bjh.16441. Epub 2020 Feb 3.
2
Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.预处理方案对首次完全缓解期接受移植的急性髓系白血病患儿预后的影响。代表欧洲血液与骨髓移植组儿科疾病工作组所做的分析
Biol Blood Marrow Transplant. 2017 Mar;23(3):467-474. doi: 10.1016/j.bbmt.2016.11.022. Epub 2016 Dec 1.
3
Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.成人复发或难治性急性髓系白血病患者序贯化疗后行减低强度预处理和异基因造血干细胞移植:来自 EBMT 急性白血病工作组的调查。
Br J Haematol. 2017 Feb;176(3):431-439. doi: 10.1111/bjh.14428. Epub 2016 Nov 23.
4
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.将移植选择扩展至50岁以上患者。急性髓系白血病患者接受减低强度预处理不匹配无关供者移植后的结局改善:欧洲血液与骨髓移植协会急性白血病工作组报告
Haematologica. 2016 Jun;101(6):773-80. doi: 10.3324/haematol.2015.138180. Epub 2016 Mar 11.
5
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果:欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
6
Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.在急性髓细胞白血病首次完全缓解的患者中进行体外和体内 T 细胞耗竭的同种异体造血干细胞移植导致相似的总生存:代表 EBMT 的 ALWP 和 MSKCC。
J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3.
7
Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).异基因造血细胞移植治疗成人急性髓系白血病第二次缓解期:日本血液细胞移植学会(JSHCT)成人急性髓系白血病工作组的回顾性研究。
Br J Haematol. 2018 Jul;182(2):245-250. doi: 10.1111/bjh.15399. Epub 2018 May 29.
8
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.一项前瞻性随机毒性研究比较了接受异基因造血干细胞移植的髓系白血病患者的低强度和清髓性预处理方案。
J Intern Med. 2013 Aug;274(2):153-62. doi: 10.1111/joim.12056. Epub 2013 Mar 25.
9
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.一项针对CD33+急性髓系白血病儿童和青少年的研究,采用减低强度预处理和异基因干细胞移植,随后逐步增加吉妥珠单抗奥唑米星靶向巩固免疫治疗剂量的I期研究。
Biol Blood Marrow Transplant. 2016 Apr;22(4):698-704. doi: 10.1016/j.bbmt.2016.01.019. Epub 2016 Jan 16.
10
Haploidentical unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT.亲缘半相合非亲缘异基因造血干细胞移植治疗复发/难治性急性髓系白血病:来自 EBMT 急性白血病工作组的 1578 例患者报告。
Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25.

引用本文的文献

1
The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.小儿急性髓系白血病造血干细胞移植的特点
Leukemia. 2025 Jul 9. doi: 10.1038/s41375-025-02685-5.
2
Advances in hematopoietic stem cells ex vivo expansion associated with bone marrow niche.与骨髓微环境相关的造血干细胞体外扩增进展。
Ann Hematol. 2024 Dec;103(12):5035-5057. doi: 10.1007/s00277-024-05773-1. Epub 2024 Apr 30.
3
Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Children and Young Adult Patients.
对于接受造血细胞移植的儿童和年轻成年急性白血病或骨髓增生异常综合征患者,持续或新发血细胞减少症比常规骨髓抽吸评估更能预测复发。
Transplant Cell Ther. 2024 Jul;30(7):692.e1-692.e12. doi: 10.1016/j.jtct.2024.04.012. Epub 2024 Apr 20.
4
Disease Status and Interval between Hematopoietic Cell Transplantations Predict Outcome of Pediatric Patients Who Undergo Subsequent Transplantation for Relapsed Hematologic Malignancy.疾病状态和造血细胞移植间隔时间可预测复发血液恶性肿瘤患儿后续移植的结果。
Transplant Cell Ther. 2024 May;30(5):526.e1-526.e11. doi: 10.1016/j.jtct.2024.02.016. Epub 2024 Feb 20.
5
Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients.儿童患者移植后复发采用无关脐血移植物进行第二次造血细胞移植后白血病得到良好控制。
Front Oncol. 2023 Aug 15;13:1221782. doi: 10.3389/fonc.2023.1221782. eCollection 2023.
6
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy.T 细胞富含的脐带血移植在高危和复发/难治性儿科髓系恶性肿瘤中提供更好的结果。
Blood Adv. 2023 May 23;7(10):2155-2165. doi: 10.1182/bloodadvances.2022009253.
7
Somatic FOXC1 insertion mutation remodels the immune microenvironment and promotes the progression of childhood acute lymphoblastic leukemia.体细胞 FOXC1 插入突变重塑免疫微环境并促进儿童急性淋巴细胞白血病的进展。
Cell Death Dis. 2022 May 3;13(5):431. doi: 10.1038/s41419-022-04873-y.
8
Sub-myeloablative Second Transplantations with Haploidentical Donors and Post-Transplant Cyclophosphamide have limited Anti-Leukemic Effects in Pediatric Patients.同种异体半相合移植后环磷酰胺在儿科患者中的抗白血病作用有限。
Transplant Cell Ther. 2022 May;28(5):262.e1-262.e10. doi: 10.1016/j.jtct.2022.02.007. Epub 2022 Feb 11.
9
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?嵌合抗原受体T细胞疗法治疗儿童B细胞前体急性淋巴细胞白血病:治愈性治疗选择还是移植桥梁?
Front Pediatr. 2022 Jan 25;9:784024. doi: 10.3389/fped.2021.784024. eCollection 2021.
10
Outcome of Intensive Therapy for Children with Relapsed Acute Myeloid Leukemia: A Single Institution Korean Study.强化治疗儿童复发急性髓系白血病的结果:单中心韩国研究。
Cancer Res Treat. 2022 Oct;54(4):1230-1239. doi: 10.4143/crt.2021.1011. Epub 2021 Dec 17.